Cargando…

Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer

OBJECTIVES: In randomized-controlled crossover design trials, overall survival (OS) treatment effect estimates are often confounded by the control group benefiting from treatment received post-progression. We estimated the adjusted OS treatment effect in EMPOWER-Lung 1 (NCT03088540) by accounting fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feliciano, Josephine Louella, McLoone, Dylan, Xu, Yingxin, Quek, Ruben G.W., Kuznik, Andreas, Pouliot, Jean-Francois, Gullo, Giuseppe, Rietschel, Petra, Guyot, Patricia, Konidaris, Gerasimos, Chan, Keith, Keeping, Sam, Wilson, Florence R., Freemantle, Nick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110970/ https://www.ncbi.nlm.nih.gov/pubmed/37082098 http://dx.doi.org/10.3389/fonc.2022.1081729

Ejemplares similares

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%
por: Freemantle, Nick, et al.
Publicado: (2022)

Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma
por: Paul, Eleanor, et al.
Publicado: (2021)

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study
por: Gümüş, Mahmut, et al.
Publicado: (2022)

Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis
por: Zhu, Gaofeng, et al.
Publicado: (2023)

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
por: Gogishvili, Miranda, et al.
Publicado: (2022)

Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
por: Lu, Tingting, et al.
Publicado: (2023)

Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations
por: Ahn, Jeffrey, et al.
Publicado: (2023)

The incidence and body site of skin cancers in the population groups of Astana, Kazakhstan
por: McLoone, Pauline, et al.
Publicado: (2018)

Cemiplimab-Induced Alopecia Areata
por: Piraccini, Bianca Maria, et al.
Publicado: (2023)

Cemiplimab-Associated Sinusoidal Obstruction Syndrome
por: Sarsour, Nadeen Y., et al.
Publicado: (2023)

Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis
por: Grace de Lima, Stacy, et al.
Publicado: (2023)

Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy
por: Ge, Wenzhen, et al.
Publicado: (2022)

Cemiplimab for cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer
Publicado: (2022)

Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer
por: Denis, Chloé, et al.
Publicado: (2021)

Intravascular squamous cell carcinoma treated with cemiplimab
por: Rose, Alexander N., et al.
Publicado: (2021)

Self‐resolving bullous pemphigoid induced by cemiplimab
por: Molle, Mattia Fabio, et al.
Publicado: (2022)

Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives
por: Mager, Layna, et al.
Publicado: (2023)

Mathematica
por: McLoone, Jon, et al.
Publicado: (1999)

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
por: Brazel, Danielle, et al.
Publicado: (2023)

Factors associated with intensive care admission in patients with lung cancer: a population-based observational study of 26, 731 patients
por: Puxty, Kathryn, et al.
Publicado: (2020)

Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again
por: Davis, Christina M., et al.
Publicado: (2022)

Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies
por: Yang, Feng, et al.
Publicado: (2021)

Second primary cancer risk - the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study
por: Coyte, Aishah, et al.
Publicado: (2014)

Diet, exercise, obesity, smoking and alcohol consumption in cancer survivors and the general population: a comparative study of 16 282 individuals
por: Wang, Z, et al.
Publicado: (2015)

Honey Combination Therapies for Skin and Wound Infections: A Systematic Review of the Literature
por: McLoone, Pauline, et al.
Publicado: (2020)

Counterpossibles in science: an experimental study
por: McLoone, Brian, et al.
Publicado: (2023)

Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
por: Lai, Fei Ya, et al.
Publicado: (2023)

Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer
por: Li, Ying, et al.
Publicado: (2022)

Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside
por: Goodman, D.T.
Publicado: (2022)

Rapid response to cemiplimab for advanced cutaneous squamous cell carcinoma
por: Zargham, Hanieh, et al.
Publicado: (2022)

Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum?
por: Boziou, Maria, et al.
Publicado: (2023)

Hypofractionated Accelerated Concurrent Chemoradiotherapy in Inoperable Stage III Non-small Cell Lung Cancer: SOCCAR. A Large Single-Centre Experience
por: Patibandla, A., et al.
Publicado: (2020)

Vogt-Koyanagi-Harada-like Syndrome Induced by Checkpoint Inhibitor Cemiplimab
por: Huang, Ye, et al.
Publicado: (2023)

Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients
por: Van Meerhaeghe, T., et al.
Publicado: (2022)

Honey: A Therapeutic Agent for Disorders of the Skin
por: McLoone, Pauline, et al.
Publicado: (2016)

Non-Melanoma Skin Cancers at Sites of Previous Frostbite: Case Report and Review
por: Imanbayev, Khalel, et al.
Publicado: (2018)

Case report: a case of diffuse unilateral subacute neuroretinitis (DUSN) in a child
por: Curragh, David S, et al.
Publicado: (2018)

Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma—A Retrospective Single-Center Study
por: Kuzmanovszki, Daniella, et al.
Publicado: (2023)

Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis
por: Li, Yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e184dphedctsoitbnari7igdu2